Combining multi-parametric MRI (mpMRI), MR-ultrasound fusion biopsy, and high intensity focused ultrasound (HIFU): A winning team in the fight against organ confined prostate cancer

JOINT EVENT:19^th Euro Congress on Cancer Science and Therapy & 25^th Cancer Nursing & Nurse Practitioners Conference

July 17-19, 2017 Lisbon, Portugal

Les Bentz

Vituro Health, USA

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

HIFU, a minimally invasive ablative therapy, has been used as an effective tool against organ confined prostate cancer for over a decade around the globe with efficacy results comparable to radical prostatectomy and radiation therapy but with the benefit to patients of much lower rates of erectile dis-function and incontinence. Due to the precise nature of HIFU, real time ultrasound imaging and the ability to modulate power for each HIFU energy pulse, the structures controlling erections and urinary continence can be avoided affording the patient better outcomes than other treatment options. Initially, HIFU was used for total gland ablation, but recently has shifted to a more focal approach due to the convergence of mpMRI and HIFU technologies. The mpMRI has excellent sensitivity in identifying clinically significant cancer tissue in the prostate with the added benefit that it is more sensitive detecting aggressive cancer tissue than clinically insignificant cancers. Exporting the information generated from the mpMRI to an MRUltrasound fusion biopsy device, a precisely targeted fusion biopsy can be performed with pinpoint accuracy and repeatability to sample suspicious tissue greatly reducing false negative biopsies and providing more accurate cancer staging information than that obtained from traditional sextant biopsies. With the best possible diagnostic data, the MR information can again be exported, this time to the HIFU therapeutic device, for fusion with live ultrasound images during ablative therapy to precisely target and destroy only the cancerous tissues with even less impact to the surrounding structures, generating outstanding patient outcomes equating to better post treatment quality of life. Patients today are being diagnosed with prostate cancer at earlier ages and this winning team of technologies provides good efficacy, is truly minimally, and delivers the patient an exceptional quality of life.

Biography :

Email: les_bentz@hotmail.com